EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 7
Issue: 8
349-354
Year: 2020

DEXAMETHASONE: COVID-19`S LAST RESORT A COMPLETE REVIEW

Maheipeube Ndang*, Gaurav Kumar Sharma and Dr. Kaushal K. Chandrul

Department of Pharmacy, Mewar University, Chittorgarh (312901), Rajasthan, India.

***Corresponding Author: Maheipeube Ndang**
Department of Pharmacy, Mewar University, Chittorgarh (312901), Rajasthan, India.

Article Received on 15/06/2020 **Article Revised on 05/07/2020** **Article Accepted on 26/07/2020**

ABSTRACT
Dexamethasone is a corticosteriod commonly used as anti-inflammatory and immunosupressant. It is cheap and globally available. Dexamethasone may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. A study found out that in Covid-19 patients dexamethasone reduced deaths by 1/3rd in ventilated patients and 1/5th in other patients receiving oxygen only.

KEYWORDS:

INTRODUCTION

Dexamethasone is a glucocorticoid that stops the discharge of drugs within the body that cause inflammation.It was initial synthesized by Duke of Edinburgh Showalter Hench in 1957.It had been introduced for medical use in 1958. It has been listed on the WHO Model List of Essential Medicines since 1977 in multiple formulations, and is currently off-patent and affordably available in most countries.

Dexamethasone is employed to treat many alternative inflammatory conditions resembling allergic disorders and skin conditions.

It is additionally accustomed treat inflammatory bowel disease, arthritis, lupus, psoriasis, and respiratory disorders.

It might also be used for functions ex-directory during this medication guide. It can be taken by using mouth, as a pill or elixir, as an injection into a muscle, intravenously, or through an eye fixed drop.It bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.

Dexamethasone's duration of action varies depending on the route. Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary- adrenal axis suppression and increased susceptibility to infections.

Randomization,trial procedures and analysis.

A baseline statistics of sufferers inclined for the trial have been accumulated which covered demographic statistics, the extent of breathing help, essential coexisting illnesses, the suitability of the trial for a selected patient, and remedy availability at trial site. Routine fitness care and registry statistics which include statistics on essential status, discharge from the health facility, and breathing and renal help remedy have been obtained.

Selected sufferers have been assigned in a 2:1 ratio to acquire the standard wellknown of care by myself or the standard wellknown care of care plus oral or intravenous dexamethasone at a dose of 6 mg as soon as every day for 10 days.

If 28-day mortality turned into 20%, then the enrollment of as a minimum 2,000 sufferers withinside the dexamethasone group and 4,000 withinside the l usual care group could offer a power of as a minimum 90% at a facet P-price of 0.01% to stumble on a clinically applicable proportional reduction of 20% between the groups.

The number one final results turned into measured primarily based totally at the mortality inside 28 days after randomization. Whereas, the secondary final results turned into measured primarily based totally at the time till discharge from the health facility and amongst sufferers now no longer receiving invasive mechanical air flow or death. Other prespecified scientific consequences covered cause-particular mortality, receipt of renal hemodialysis or hemofiltration essential cardiac arrhythmia and receipt, and length of air flow. The risk ratio from Cox regression turned into carried out for the number one final results of 28-day mortality. Kaplan

Meier survival curves have been built to expose cumulative mortality over the 28-day period. Cox regression turned into extensively utilized to decide the secondary final results of health facility discharge inside 28 days with censoring of statistics on the next day for sufferers who had died at some point of hospitalization. The log- binomial regression version turned into carried out to calculate the chance ratio amongst sufferers now no longer receiving invasive mechanical air flow at randomization. Since the mean age turned into 1.1 years older amongst sufferers in dexamethasone, to stability the rate ratio have been adjusted for the baseline age into <70 years, 70-79 years and >80 years.

Table 1. Characteristics of the Patients at Baseline, According to Treatment Assignment and Level of Respiratory Support.*

Characteristic	Treatment Assignment		Respiratory Support Received at Randomization		
	Dexamethasone (N=2104)	Usual Care (N=4321)	No Receipt of Oxygen (N=1535)	Oxygen Only (N=3883)	Invasive Mechanical Ventilation (N=1007)
Age†					
Mean — yr	66.9±15.4	65.8±15.8	69.4±17.5	66.7±15.3	59.1±11.4
Distribution — no. (%)					
<70 yr	1141 (54)	2504 (58)	659 (43)	2148 (55)	838 (83)
70 to 79 yr	469 (22)	859 (20)	338 (22)	837 (22)	153 (15)
≥80 yr	494 (23)	958 (22)	538 (35)	898 (23)	16 (2)
Sex — no. (%)					
Male	1338 (64)	2749 (64)	891 (58)	2462 (63)	734 (73)
Female‡	766 (36)	1572 (36)	644 (42)	1421 (37)	273 (27)
Median no. of days since symptom onset (IQR)§	8 (5–13)	9 (5–13)	6 (3–10)	9 (5–12)	13 (8–18)
Median no. of days since hospitalization (IQR)	2 (1–5)	2 (1–5)	2 (1–6)	2 (1–4)	5 (3–9)
Respiratory support received — no. (%)					
No oxygen	501 (24)	1034 (24)	1535 (100)	NA	NA
Oxygen only	1279 (61)	2604 (60)	NA	3883 (100)	NA
Invasive mechanical ventilation	324 (15)	683 (16)	NA	NA	1007 (100)
Previous coexisting disease					
Any	1174 (56)	2417 (56)	911 (59)	2175 (56)	505 (50)
Diabetes	521 (25)	1025 (24)	342 (22)	950 (24)	254 (25)
Heart disease	586 (28)	1171 (27)	519 (34)	1074 (28)	164 (16)
Chronic lung disease	415 (20)	931 (22)	351 (23)	883 (23)	112 (11)
Tuberculosis	6 (<1)	19 (<1)	8 (1)	11 (<1)	6 (1)
HIV infection	12 (1)	20 (<1)	5 (<1)	21 (1)	6 (1)
Severe liver disease¶	37 (2)	82 (2)	32 (2)	72 (2)	15 (1)
Severe kidney impairment‖	166 (8)	358 (8)	119 (8)	253 (7)	152 (15)
SARS-CoV-2 test result					
Positive	1850 (88)	3848 (89)	1333 (87)	3416 (88)	949 (94)
Negative	247 (12)	453 (10)	193 (13)	452 (12)	55 (5)
Test result not yet known	7 (<1)	20 (<1)	9 (1)	15 (<1)	3 (<1)

* Plus–minus values are means ±SD. HIV denotes human immunodeficiency virus, IQR interquartile range, NA not applicable, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.
† There was a significant (P=0.01) difference in the mean age between patients in the dexamethasone group and those in the usual care group, but there were no significant differences between the groups in any other baseline characteristic.
‡ Included in this category were 6 pregnant women.
§ Data regarding the number of days since symptom onset were missing for 4 patients in the dexamethasone group and 13 patients in the usual care group; these patients were excluded from estimates of the median number of days since onset.
¶ Severe liver disease was defined as requiring ongoing specialist care.
‖ Severe kidney impairment was defined as an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 m^2.



Dexamethasone was being examined on sufferers as a part of the randomized assessment of the Covid-19 remedy trial, primarily based totally at Oxford University. During the trial, a complete of 2,104 sufferers are assigned to acquire dexamethasone 6mg in step with day, both through mouth or through intravenous injection, for 20 days and had been in comparison with a manipulate organization of 4,321 sufferers randomized to regular care alone. Among the sufferers withinside the manipulate organization, mortality after 28 days changed into observed to be maximum in people who required ventilation (41%), intermediate in the ones sufferers who required oxygen only (25%), and lowest amongst people who did now no longer require any breathing intervention (13%). The consequences cautioned that dexamethasone decreased deaths through 35% in ventilated sufferers and through 20% in every other sufferers receiving oxygen only. There had been no blessings amongst the ones sufferers who did now no longer require breathing support. Based on those consequences, demise might be avoided through the remedy of round ei ght ventilated sufferers or round 25 sufferers requiring oxygen alone.



Mortality at 28 days in all patients and according to Respiratory support randomization.



Effect of Dexamethasone on 28-day mortality based on randomization.

The primary outcome of the trial shows that death rate was lower in the dexamethasone group than the usual care group, with 482 deaths out of 2104 and in 1110 of 4321 patients. Whereas the secondary outcome reveals that sufferers in the dexamethasone group had a shorter duration of hospitalization than those in the usual care group and a greater probability of discharge alive within 28 days.

Table 2. Primary and Secondary Outcomes.

Outcome	Dexamethasone (N=2104)	Usual Care (N=4321)	Rate or Risk Ratio (95% CI)*
	no./total no. of patients (%)		
Primary outcome			
Mortality at 28 days	482/2104 (22.9)	1110/4321 (25.7)	0.83 (0.75–0.93)
Secondary outcomes			
Discharged from hospital within 28 days	1413/2104 (67.2)	2745/4321 (63.5)	1.10 (1.03–1.17)
Invasive mechanical ventilation or death†	456/1780 (25.6)	994/3638 (27.3)	0.92 (0.84–1.01)
Invasive mechanical ventilation	102/1780 (5.7)	285/3638 (7.8)	0.77 (0.62–0.95)
Death	387/1780 (21.7)	827/3638 (22.7)	0.93 (0.84–1.03)

* Rate ratios have been adjusted for age with respect to the outcomes of 28-day mortality and hospital discharge. Risk ratios have been adjusted for age with respect to the outcome of receipt of invasive mechanical ventilation or death and its subcomponents.
† Excluded from this category are patients who were receiving invasive mechanical ventilation at randomization.

Dexamethasone is commonly safe. It affords a good advantage-danger profile, mainly in sufferers with excessive types of pneumonia, whilst the advantage is much less distinguished in sufferers with non-excessive pneumonia. As the remedy is brief, even at excessive doses, corticosteroids aren't related to severe aspect effects. Potentially better blood glucose levels (hyperglycemia) are temporary.

Prolonged use (I.E., used for greater than weeks) can be related to unfavorable activities together with glaucoma, cataract, fluid retention, hypertension, mental effects (e.G., temper swings, reminiscence issues, confusion or irritation), weight gain, or elevated danger of infections and osteoporosis.

To reiterate: All those unfavorable activities aren't related to brief-time period use (aside from hyperglycemia that may get worse diabetes).

REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020; 382: 727-733.
2. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis, 2020; 20: 669-677.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020; 395: 1054-1062.
4. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020; 395: 507-513.
5. Cao J, Tu W-J, Cheng W, et al. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clin Infect Dis 2020 April 2 (Epub ahead of print).
6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med, 2020; 46: 846-848.
7. Docherty AB, Harrison EM, Green CA, et al. Features of 20,133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ, 2020; 369: m1985-m1985.
8. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa2007764.
9. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis 2020 June 8 (Epub ahead of print).
10. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med, 2006; 12: 1203-1207.
11. Wong CK, Lam CWK, Wu AKL, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol, 2004; 136: 95-103.
12. Baillie JK, Digard P. Influenza — time to target the host? N Engl J Med, 2013; 369: 191-193.
13. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020; 395: 497-506.
14. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science, 2020; 368: 473-474.
15. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet, 2020; 395: 683-684.
16. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020; 395: 473-475.

17. Corral L, Bahamonde A, Arnaiz de las Revillas F, et al. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. June 18, 2020 (https://www.medrxiv.org/content/10.1101/2020.06.17.20133579v1. opens in new tab). preprint.
18. Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review. BMJ, 2020; 369: m1936-m1936.
19. Zhao JP, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi, 2020; 43: 183-184. (In Chinese.).
20. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020; 323: 1061-1069.
21. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ, 2020; 368: m606-m606.
22. Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med, 2020; 8: 267-276.
23. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med, 1984; 3: 409-422.
24. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, 1988; 2: 349-360.
25. Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med, 2020; 382: 674-678.
26. Rojek AM, Horby PW. Modernising epidemic science: enabling patient-centred research during epidemics. BMC Med, 2016; 14: 212-212.
27. Whitty C. Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals. London: Medicines and Healthcare Products Regulatory Agency, June
28. 16, 2020 (https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?A lertID=103054. opens in new tab).
29. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med, 2006; 3(9): e343-e343.
30. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med, 2018; 197: 757-767.
31. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med 2020;48(2):e98-e106.
32. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta- analysis. Ann Intern Med, 2015; 163: 519-528.
33. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol, 2004; 31: 304-309.
34. Lee N, Chan PKS, Hui DSC, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis, 2009; 200: 492-500.
35. Cheng PKC, Wong DA, Tong LKL, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet, 2004; 363: 1699- 1700.
36. To KK-W, Tsang OT-T, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis, 2020; 20: 565-574.
37. Zhou R, Li F, Chen F, et al. Viral dynamics in asymptomatic patients with COVID-19. Int J Infect Dis, 2020; 96: 288-290.
38. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med, 2020; 26: 672-675.
39. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature, 2020; 581: 465-469.
40. COVID-19 treatment guidelines. Bethesda, MD: National Institutes of
41. Health, 2020 (https://www.covid19treatmentguidelines.nih.gov/dexamethasone/. opens in new tab).